BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28418851)

  • 21. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
    Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
    Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
    Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
    Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
    Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
    González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
    Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
    Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
    Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
    Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
    Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
    Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
    Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
    Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
    Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
    Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic Value of Corrected Levels of Serum Calcium and Serum Lactate Dehydrogenase for Newly Diagnosed Multiple Myeloma Patients].
    Xie YM; Cui YJ; Li H; Pan XR; Xu YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):844-849. PubMed ID: 31204942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC; Maltezas D; Tzenou T; Koulieris E; Bradwell AR
    Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma.
    Huang B; Lu J; Wang X; Xiao Y; Zhao Y; Huang H; Liu J; Chen M; Gu J; Yuan S; Zheng D; Li Y; Huang X; Li J
    Leuk Lymphoma; 2017 Jul; 58(7):1740-1742. PubMed ID: 27881052
    [No Abstract]   [Full Text] [Related]  

  • 38. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
    Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
    Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
    Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
    Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural history of multiple myeloma with de novo del(17p).
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.